Related references
Note: Only part of the references are listed.Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
Scott T. Tagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y. Fradet et al.
ANNALS OF ONCOLOGY (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
Petros Grivas et al.
CANCER (2019)
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
Lelia Maria de Almeida Carvalho et al.
JAMA NETWORK OPEN (2019)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies
Pedro C. Barata et al.
TARGETED ONCOLOGY (2018)
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
David M. Goldenberg et al.
Oncotarget (2018)
A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First-and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany
Guenter Niegisch et al.
JOURNAL OF CANCER (2018)
Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).
Srikala S. Sridhar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Antibody-Drug Conjugates in Bladder Cancer
Panagiotis J. Vlachostergios et al.
BLADDER CANCER (2018)
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
Rebecca Suk Heist et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer
Chiara Avellini et al.
ONCOTARGET (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.
Waddah Arafat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Allyson J. Ocean et al.
CANCER (2017)
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2017)
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
D. Raggi et al.
ANNALS OF ONCOLOGY (2016)
Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
Bishoy Faltas et al.
CLINICAL GENITOURINARY CANCER (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
Thomas M. Cardillo et al.
BIOCONJUGATE CHEMISTRY (2015)
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N. Starodub et al.
CLINICAL CANCER RESEARCH (2015)
Third-Line Chemotherapy for Metastatic Urothelial Cancer A Retrospective Observational Study
Giuseppe Di Lorenzo et al.
MEDICINE (2015)
The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience
Richard M. Bambury et al.
ONCOLOGIST (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Upregulation of Trop-2 quantitatively stimulates human cancer growth
M. Trerotola et al.
ONCOGENE (2013)
Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling
Tanya Stoyanova et al.
GENES & DEVELOPMENT (2012)
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Thomas M. Cardillo et al.
CLINICAL CANCER RESEARCH (2011)
Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues: Potential Implications as a Cancer Therapeutic Target
Lara P. Stepan et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2011)
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer
Y. J. Fang et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
TROP2 expression as prognostic marker for gastric carcinoma
G. Muehlmann et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
High expression of TROP2 correlates with poor prognosis in pancreatic cancer
D. Fong et al.
BRITISH JOURNAL OF CANCER (2008)
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity
Dominic Fong et al.
MODERN PATHOLOGY (2008)
Clinical significance of TROP2 expression in colorectal cancer
Takahiro Ohmachi et al.
CLINICAL CANCER RESEARCH (2006)
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: A phase 2 study
S Krege et al.
JOURNAL OF UROLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
